These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38728364)

  • 1. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
    Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
    Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
    J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
    Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    Ychou M; Rivoire M; Thezenas S; Guimbaud R; Ghiringhelli F; Mercier-Blas A; Mineur L; Francois E; Khemissa F; Chauvenet M; Kianmanesh R; Fonck M; Houyau P; Aparicio T; Galais MP; Audemar F; Assenat E; Lopez-Crapez E; Jouffroy C; Adenis A; Adam R; Bouché O
    Br J Cancer; 2022 May; 126(9):1264-1270. PubMed ID: 34992255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
    Saridaki Z; Androulakis N; Vardakis N; Vamvakas L; Kabouraki E; Kalbakis K; Hatzidaki D; Voutsina A; Mavroudis D; Georgoulias V; Souglakos J
    Br J Cancer; 2012 Dec; 107(12):1932-7. PubMed ID: 23169296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
    Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
    Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.